Background: Bevacizumab (BEV) plus chemotherapy as a neoadjuvant regimen presents good efficacy in patients with locally advanced cancer. However, its role in patients with locally advanced gastric cancer (LAGC) is not clear. Thus, the study aimed to assess the efficacy and safety of neoadjuvant BEV plus chemotherapy in patients with LAGC.

Methods: Twenty resectable patients with LAGC who received BEV plus docetaxel/cisplatin/capecitabine (DCC) chemotherapy for 3 cycles with 21 days as one cycle as neoadjuvant regimen were involved. Besides, their treatment response, survival profiles, and adverse events were assessed.

Results: In total, two (10.0%), 9 (45.0%), 8 (40.0%), and 1 (5.0%) patients achieved complete remission, partial remission, stable disease, and progressive disease (PD) according to imaging evaluation, which resulted in 55.0% of objective response rate and 95.0% of disease control rate, respectively. Moreover, the number of patients with pathological response grades 1, 2, and 3 was 8 (40.0%), 8 (40.0%), and 3 (15.0%); while 1 (5.0%) patient did not receive surgery due to PD, thus the data of this patient was not assessable. Meanwhile, 18 (90.0%) patients achieved R0 resection. Regarding survival profile, the median disease-free survival or overall survival were both not reached. The 1-year, 2-, and 3-year disease-free survival rates were 88.8, 80.7, and 67.3%. Meanwhile, the 1-, 2-, and 3-year overall survival rates were 100.0%, 75.8%, and 75.8%, respectively. Additionally, the main adverse events were anemia (90.0%), alopecia (90.0%), leukopenia (70.0%), and anorexia (65.0%). Indeed, most adverse events were of grade 1 or 2 and were manageable.

Conclusion: Neoadjuvant BEV plus DCC chemotherapy presents a favorable pathological response and survival profile with acceptable safety in patients with LAGC.

Keywords: Bevacizumab plus chemotherapy, neoadjuvant regimen, treatment response, survival data, adverse events
INTRODUCTION

Gastric cancer is one of the most common malignancies worldwide, which affects ~990,000 people and causes around 738,000 deaths every year (1–3). In China, the incidence of gastric cancer is ~30.64 per 100,000 populations per year (4). In all gastric cancer, locally advanced gastric cancer (LAGC) is a special type since the prognosis of patients with LAGC is dramatically different between resectable and unresectable ones (5–7); therefore, creating surgery opportunities for the patients with unresectable LAGC by neoadjuvant chemotherapy is necessary (8–11). Meanwhile, it is also critical to optimize surgical conditions for the patients with resectable LAGC by neoadjuvant chemotherapy, which reduces postoperative recurrence, thus further improving survival in these patients (12–14). Among the regimens of neoadjuvant chemotherapy, docetaxel, cisplatin, and capecitabine (DCC), chemotherapy is tolerable and brings promising efficacy with a 5-year survival rate of 54% in R0 patients with resected LAGC (15).

Bevacizumab (BEV), an angiogenesis inhibitor, binds to vascular endothelial growth factor (VEGF)-A to prevent the interaction of VEGF-A with the VEGF receptor, then suppresses the VEGF signaling pathway, thereby inhibiting neovascularization (16, 17). Nowadays, BEV plus chemotherapy as a neoadjuvant regimen is used in patients with locally advanced cancers (14, 18, 19). For instance, neoadjuvant BEV plus oxaliplatin, leucovorin, and 5-fluorouracil realize a pathological downsizing rate of 65% in locally advanced rectal cancer patients (14); moreover, another research illustrates that BEV plus paclitaxel and carboplatin as a neoadjuvant regimen achieves 100% objective response rate (ORR) and an optimal pathological response of 38% in patients with locally advanced cervical cancer (18); besides, as for unresectable stage III lung adenocarcinoma patients, neoadjuvant BEV plus pemetrexed and carboplatin induces pathologic downsizing rate of 73.8% and 1-year event-free survival rate of 56.1% (19). Based on the above-mentioned information, we hypothesized that BEV plus chemotherapy as neoadjuvant therapy might be a promising regimen in LAGC, while it is rarely applied in LAGC.

The current pilot study aimed to investigate the efficacy and safety of neoadjuvant BEV plus DCC in patients with resectable LAGC.

METHODS

Patients

This study serially recruited twenty patients with LAGC who were about to receive BEV plus DCC as a neoadjuvant regimen from July 2017 to December 2019. The patients were recruited in the study if they met the following criteria: (i) diagnosed as gastric adenocarcinoma pathologically and histologically; (ii) over 18 years old; (iii) clinical tumor-node-metastasis (cTNM) stage III (cT3 to cT4a, cN+, and cM0) according to the eighth edition of TNM classification (20); (iv) Eastern Cooperative Oncology Group (ECOG) score 0 to 1; (v) with resectable tumor; (vi) about to receive BEV plus DCC as a neoadjuvant regimen. The patients were excluded from the study if they had any of the following conditions: (i) had other carcinoma or malignancy; (ii) allergic to the drugs used in the study; (iii) unwilling to be followed up regularly; (iv) during pregnancy or breastfeeding. The study was approved by the Institutional Review Board. All patients provided written informed consents.

Treatment

The patients underwent BEV plus DCC as a neoadjuvant regimen for 3 cycles with 21 days as one cycle. At 4 weeks after the end of the last neoadjuvant therapy cycle, the tumor resectability was evaluated again based on the CT examinations in terms of the Japanese classification of gastric carcinoma (21), then the surgical resection was performed if the patient’s tumor was deemed resectable. At 4–8 weeks after surgery, the patients continued to receive DCC adjuvant therapy for 3 cycles depending on the patient’s recovery. The recommended regimen of neoadjuvant therapy was as followed: BEV was administered intravenously at the dose of 7.5 mg/kg on day 1; docetaxel was administered intravenously at the dose of 60 mg/m² on day 1; cisplatin was administered intravenously at the dose of 60 mg/m² on day 1; capecitabine was administered orally at the dose of 93.75 mg/m² twice daily from day 1 to day 14 (22). The specific dose of the above regimen was allowed to be adjusted depending on the patients’ response and tolerance.

Outcome Assessment

At 4 weeks after the end of the last neoadjuvant therapy cycle, clinical response was evaluated based on CT examinations according to the Response Evaluation Criteria in Solid Tumors (RECIST) (23), including complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD), based on which, the ORR and the disease control rate (DCR) were calculated. During surgery, the pathological response was assessed based on intraoperative pathological examinations in accordance with the Japanese classification of gastric carcinoma (21), which was classified into four grades: (i) grade 0, there was no evidence of effect; (ii) grade 1, there were viable tumor cells (the cells judged to be capable of proliferating) in more than 1/3 of the tumor areas; (iii) grade 2, there were viable tumor cells in <1/3 of the tumor areas; (iv) grade 3, there were no viable tumor cells in the tumor areas. After surgery, the R0 resection rate was evaluated based on the resection margin of formalin-fixed paraffin-embedded (FFPE) tumor specimens, and R0 resection was defined as the resection without remaining macroscopic or microscopic residual lesion. In addition, adverse events were recorded to assess the treatment safety and were graded in terms of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, version 4.0).

Follow-Up

All patients were followed up regularly until January 2021, and the median follow-up period was 20.1 months with the range of 7.5–36.1 months. On the basis of the follow-up data, disease-free survival (DFS) and overall survival (OS) were calculated. DFS was defined as the duration from surgery to the disease relapse or the patient’s death; OS was defined as the duration from surgery to the patient’s death (24).
Statistical Analysis
Count data were expressed as percentages, and measurement data were presented as mean ± SD. DFS and OS were constructed with the Kaplan-Meier curves. SPSS 26.0 (IBM Corp., Armonk, New York, USA) and GraphPad Prism 7.02 (GraphPad Software Inc., San Diego, California, USA) were applied for statistical analysis and figure plotting, respectively.

RESULTS
Patients’ Characteristics
A total of 20 patients with LAGC were enrolled in the study, who presented a mean age of 58.1 ± 9.8 years with 8 (40.0%) females and 12 (60.0%) males. In terms of tumor differentiation, 1 (5.0%) patient was of good differentiation, 6 (30.0%) patients were of moderate differentiation, and 13 (65.0%) patients were of poor differentiation. The number of patients with cT3 stage and cT4a stage was 5 (25.0%) and 15 (75.0%) respectively. As for the cN stage, there were 7 (35.0%) patients with cN1 stage, 7 (35.0%) patients with cN2 stage, and 6 (30.0%) patients with cN3 stage. The detailed clinical features were shown in Table 1.

Treatment Response
All patients completed 3 cycles of BEV plus chemotherapy as neoadjuvant therapy, and no patient violated the protocol due to side effects. After neoadjuvant therapy, 2 (10.0%) patients achieved CR, 9 (45.0%) patients achieved PR, 8 (40.0%) patients had SD, and 1 (5.0%) patient had PD (Figure 1A). Therefore, the ORR (CR+PR) was 55.0% and the DCR (CR+PR+SD) was 95.0% (Figure 1B).

During surgery, the pathological response was evaluated. The number of patients with pathological response grades 1, 2, and 3 were 8 (40.0%), 8 (40.0%), and 3 (15.0%); while 1 (5.0%) patient did not receive surgery due to PD, thus the data of this patient was not assessable (Figure 2A).

After surgery, R0 resection was also assessed, which showed that 18 (90.0%) patients achieved the criteria, while only 1 (5.0%) patient did not achieve it; the data of 1 (5.0%) patient was not assessable for the same reason mentioned above (Figure 2B).

DFS and OS
During a median follow-up of 20.1 months (range: 7.5–36.1 months), the median DFS and OS were both not reached. The 1-, 2-, and 3-year DFS rates were 88.8%, 80.7%, and 67.3%, respectively (Figure 3A). Meanwhile, the 1-, 2-, and 3-year OS were 100.0%, 75.8%, and 75.8%, respectively (Figure 3B).

Adverse Events
The most common hematological adverse events were anemia (90.0%), leukopenia (70.0%), neutropenia (60.0%), and thrombocytopenia (35.0%); meanwhile, the most frequent non-hematological adverse events were alopecia (90.0%), anorexia (65.0%), and fatigue (45.0%) (Table 3).

DISCUSSION
Neoadjuvant chemotherapy has been extensively applied in patients with LAGC (25, 26). For instance, neoadjuvant DCC shows an R0 resection rate of 86.7% and R1 resection rate of 4.5% in patients with resectable gastric cancer (25); in patients with LAGC, neoadjuvant docetaxel, cisplatin, and S-1 realizes a partial response rate of 57% and an SD rate of 43%; meanwhile, it also facilitates a pathological response grade 1a in 17% patients, grade 1b in 30% patients, grade 2 in 37% patients and grade 3 in 17% patients (26). Recently, a trial reports that BEV plus DCC as neoadjuvant regimen presents pleasing treatment response in previous patients with unresectable LAGC or paraaortic lymph node metastatic gastric cancer, and the data shows that the ORR is 64.3%; meanwhile, the pathological complete regression rate is 12.9% (22), which indicates that neoadjuvant BEV plus DCC may improve treatment response in patients with gastric cancer.

TABLE 1 | Clinical characteristics.

| Items                        | LAGC patients (N = 20) |
|------------------------------|------------------------|
| Age (years), mean ± SD       | 58.1 ± 9.8             |
| Gender, No. (%):             |                        |
| Female                       | 8 (40.0)               |
| Male                         | 12 (60.0)              |
| Current smoke, No. (%):      |                        |
| Current drink, No. (%):      |                        |
| Hypertension, No. (%):       |                        |
| Hyperlipidemia, No. (%):     |                        |
| Diabetes, No. (%):           |                        |
| H. pylori infection, No. (%):|                        |
| Negative                     | 13 (65.0)              |
| Positive                     | 7 (35.0)               |
| Tumor location, No. (%):     |                        |
| Cardia                       | 8 (40.0)               |
| Gastric body                 | 9 (45.0)               |
| Gastric antrum               | 3 (15.0)               |
| Differentiation, No. (%):    |                        |
| Well                         | 1 (5.0)                |
| Moderate                     | 6 (30.0)               |
| Poor                         | 13 (65.0)              |
| cT stage, No. (%):           |                        |
| cT3                          | 5 (25.0)               |
| cT4a                         | 15 (75.0)              |
| cN stage, No. (%):           |                        |
| cN1                          | 7 (35.0)               |
| cN2                          | 7 (35.0)               |
| cN3                          | 6 (30.0)               |

LAGC, locally advanced gastric cancer; SD, standard deviation; H. pylori, helicobacter pylori; cT, clinical tumor; cN, clinical node.

3 adverse events were anemia (15.0%), leukopenia (20.0%), neutropenia (25.0%), thrombocytopenia (5.0%), anorexia (5.0%), diarrhea (5.0%), and elevated transaminase (5.0%).
FIGURE 1 | Clinical response. The percentage of patients with locally advanced gastric cancer (LAGC) with complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD) (A); the percentage of LAGC patients with objective response rate (ORR) and disease control rate (DCR) (B).

FIGURE 2 | Pathological response and R0 resection. The percentage of patients with LAGC with grade 1, grade 2, and grade 3 pathological response (A); the percentage of patients with LAGC with R0 resection and without R0 resection (B).

FIGURE 3 | Survival profile. Accumulating DFS rate (A) and accumulating OS rate (B). Dotted line represents the 95% CI of DFS or OS.

Thus, our study further explored the role of neoadjuvant BEV plus DCC in patients with LAGC and discovered that BEV plus DCC as neoadjuvant therapy presented a good clinical response, with an ORR of 55.0% and a pathological response grade 2 in 40.0% of patients and grade 3 in 15.0% patients, which was numerically better than DCC chemotherapy alone as neoadjuvant therapy (25). The explanations might be that (1) BEV could inhibit the neovascularization and induce the regression of tumor blood vessels (16), meanwhile, chemotherapy exhibited the ability of anti-cancer cytotoxicity (27), therefore, BEV plus DCC might present a better anti-tumor effect; (2) BEV might enhance the chemosensitivity of gastric cancer cells via suppressing the VEGF-phosphatidylinositol 3 kinase/protein kinase B-survivin signaling cascade (28); thus, it combined with DCC could induce favorable outcomes.

Neoadjuvant chemotherapy has been reported to improve survival in patients with LAGC. For example, neoadjuvant DCC chemotherapy displays acceptable survival with the median
### TABLE 2 | Key characteristics and treatment outcomes of each patient.

| No. | Age (years) | Gender | Tumor location | Differentiation | cT stage | cN stage | Clinical response | Resection | R0 resection | Pathological response | Relapse | DFS (months) | Death | OS (months) |
|-----|-------------|--------|----------------|-----------------|----------|----------|------------------|-----------|--------------|--------------------|---------|--------------|-------|-------------|
| 1   | 63          | Female | Cardia         | Moderate        | cT4a     | cN3      | SD               | Yes       | Yes          | Grade 1            | No      | 21.7         | No    | 21.7        |
| 2   | 67          | Female | Gastric antrum | Poor            | cT3      | cN1      | CR               | Yes       | Yes          | Grade 3            | No      | 36.1         | No    | 36.1        |
| 3   | 46          | Male   | Cardia         | Moderate        | cT4a     | cN2      | PR               | Yes       | Yes          | Grade 2            | No      | 25.1         | No    | 25.1        |
| 4   | 52          | Male   | Gastric body   | Poor            | cT3      | cN1      | SD               | Yes       | Yes          | Grade 2            | No      | 10.3         | No    | 10.3        |
| 5   | 57          | Male   | Gastric body   | Poor            | cT4a     | cN2      | PR               | Yes       | Yes          | Grade 2            | No      | 8.8          | No    | 8.8         |
| 6   | 56          | Female | Cardia         | Moderate        | cT3      | cN1      | CR               | Yes       | Yes          | Grade 3            | No      | 31.4         | No    | 31.4        |
| 7   | 46          | Female | Gastric body   | Well            | cT4a     | cN3      | PR               | Yes       | Yes          | Grade 1            | No      | 7.5          | No    | 7.5         |
| 8   | 63          | Male   | Gastric body   | Poor            | cT4a     | cN1      | PR               | Yes       | Yes          | Grade 2            | No      | 16.2         | No    | 16.2        |
| 9   | 72          | Female | Cardia         | Poor            | cT4a     | cN1      | SD               | Yes       | Yes          | Grade 1            | Yes     | 6.3          | Yes   | 13.1        |
| 10  | 45          | Male   | Gastric body   | Poor            | cT4a     | cN1      | SD               | Yes       | Yes          | Grade 1            | No      | 18.1         | No    | 18.1        |
| 11  | 69          | Male   | Cardia         | Poor            | cT4a     | cN1      | SD               | Yes       | Yes          | Grade 1            | Yes     | 24.5         | No    | 27.3        |
| 12  | 61          | Male   | Gastric body   | Poor            | cT3      | cN1      | PR               | Yes       | Yes          | Grade 2            | No      | 28.0         | No    | 28.0        |
| 13  | 64          | Male   | Gastric antrum | Poor            | cT4a     | cN3      | PD               | No        | -            | -                  | -       | -            | -     | -           |
| 14  | 57          | Male   | Cardia         | Moderate        | cT4a     | cN2      | PR               | Yes       | Yes          | Grade 1            | No      | 22.5         | No    | 22.5        |
| 15  | 68          | Male   | Cardia         | Poor            | cT4a     | cN3      | SD               | Yes       | No           | Grade 1            | Yes     | 9.1          | Yes   | 19.5        |
| 16  | 43          | Male   | Gastric body   | Moderate        | cT4a     | cN3      | PR               | Yes       | Yes          | Grade 2            | No      | 26.2         | No    | 26.2        |
| 17  | 68          | Female | Gastric antrum | Moderate        | cT4a     | cN2      | PR               | Yes       | Yes          | Grade 2            | No      | 20.1         | No    | 20.1        |
| 18  | 60          | Male   | Gastric body   | Poor            | cT3      | cN2      | PR               | Yes       | Yes          | Grade 3            | No      | 13.9         | No    | 13.9        |
| 19  | 65          | Male   | Gastric body   | Poor            | cT4a     | cN2      | SD               | Yes       | Yes          | Grade 2            | Yes     | 17.3         | Yes   | 21.1        |
| 20  | 39          | Female | Cardia         | Poor            | cT4a     | cN2      | SD               | Yes       | Yes          | Grade 1            | No      | 13.2         | No    | 13.2        |

* cT, clinical tumor; cN, clinical node; DFS, disease-free survival; OS, overall survival; SD, stable disease; CR, complete remission; PR, partial remission; PD, progressive disease.
TABLE 3 | Adverse events.

| Items                              | Total | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|-----------------------------------|-------|---------|---------|---------|---------|
| **Hematological adverse events**  |       |         |         |         |         |
| Anemia, No. (%)                   | 18(90.0) | 10(50.0) | 5(25.0) | 3(15.0) | 0(0.0)  |
| Leukopenia, No. (%)               | 14(70.0) | 7(35.0)  | 3(15.0) | 4(20.0) | 0(0.0)  |
| Neutropenia, No. (%)              | 12(60.0) | 5(25.0)  | 2(10.0) | 5(25.0) | 0(0.0)  |
| Thrombocytopenia, No. (%)         | 7(35.0)  | 4(20.0)  | 2(10.0) | 1(5.0)  | 0(0.0)  |
| **Non-hematological adverse events** |       |         |         |         |         |
| Alopecia, No. (%)                 | 18(90.0) | 14(70.0) | 4(20.0) | 0(0.0)  | 0(0.0)  |
| Anorexia, No. (%)                 | 13(65.0) | 8(40.0)  | 4(20.0) | 1(5.0)  | 0(0.0)  |
| Fatigue, No. (%)                  | 9(45.0)  | 6(30.0)  | 3(15.0) | 0(0.0)  | 0(0.0)  |
| Nausea and vomiting, No. (%)      | 8(40.0)  | 5(25.0)  | 3(15.0) | 0(0.0)  | 0(0.0)  |
| Diarrhea, No. (%)                 | 6(30.0)  | 4(20.0)  | 1(5.0)  | 1(5.0)  | 0(0.0)  |
| Hand-foot syndrome, No. (%)       | 5(25.0)  | 2(10.0)  | 3(15.0) | 0(0.0)  | 0(0.0)  |
| Hypertension, No. (%)             | 4(20.0)  | 3(15.0)  | 1(5.0)  | 0(0.0)  | 0(0.0)  |
| Elevated transaminase, No. (%)    | 4(20.0)  | 2(10.0)  | 1(5.0)  | 1(5.0)  | 0(0.0)  |
| Constipation, No. (%)             | 3(15.0)  | 2(10.0)  | 1(5.0)  | 0(0.0)  | 0(0.0)  |
| Pruritus, No. (%)                 | 3(15.0)  | 2(10.0)  | 1(5.0)  | 0(0.0)  | 0(0.0)  |
| Proteinuria, No. (%)              | 3(15.0)  | 1(5.0)   | 2(10.0) | 0(0.0)  | 0(0.0)  |

Some limitations still existed in our study: (1) we did not enroll patients with LAGC receiving neoadjuvant DCC chemotherapy as control, therefore, further randomized controlled trial could be performed; (2) the sample size of this study was only 20 patients because the usage of BEV as neoadjuvant therapy in patients with LAGC remained in exploring stage, thus, a subsequent study with larger sample size was needed to verify our conclusion; (3) the follow-up time was relatively short, which might affect the DFS and OS evaluation in statistics; (4) the effect of other anti-angiogenesis agents (such as apatinib) combining with chemotherapy as a neoadjuvant regimen in LAGC could be investigated further.

In conclusion, neoadjuvant BEV plus DCC presents a favorable pathological response and survival profile with acceptable safety in patients with LAGC. The results of this study highlight that BEV plus DCC is a potentially neoadjuvant regimen that may achieve survival benefits in patients with LAGC.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Institutional Review Board of the People’s Hospital of XiaJin Affiliated to Shandong First Medical University. The patients/participants provided their written informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
DY and TH contributed to the study design and manuscript writing. DY, ZW, TH, and LY conducted literature research and clinical practice. DY, ZW, and TH contributed to the data acquisition and analysis. DY and TH reviewed the manuscript and made revisions. All authors read and approved the final manuscript. The figures were made by the authors’ own work. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. (2020) 21:4012. doi: 10.3390/ijms2114012
2. Strong VE. Progress in gastric cancer. Updates Surg. (2018) 70:157–59. doi: 10.1007/s13304-018-0543-3
3. Xiao S, Zhou L. Gastric cancer: metabolic and metabolomics perspectives (Review). Int J Oncol. (2017) 51:5–17. doi: 10.3892/ijo.20.17.4000
4. Yang X, Zhang T, Zhang H, Sang S, Chen H, Zuo X. Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia. Biomark Res. (2021) 9:84. doi: 10.1186/s40634-021-00340-6
5. Hashimoto T, Kurokawa Y, Mori M, Doki Y. Update on the treatment of gastric cancer. JMA J. (2018) 1:40–9. doi: 10.3166/jmaj.2018.8-0006
6. Ison DH. Advances in the treatment of gastric cancer: 2019. Curr Opin Gastroenterol. (2019) 35:551–54. doi: 10.1097/MOG.0000000000000577
7. Thakur B, Devkota M, Abraham, Chaudhary M. Evidence based surgical approach to locally advanced gastric cancer. J Nepal Health Res Council. (2019) 17:133–40. doi: 10.33341/jnhrc.v0i10.2055
8. Coccodini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S, et al. Neoadjuvant chemotherapy in advanced gastric and esophageo-gastric cancer: Meta-analysis of randomized trials. Int J Surg. (2018) 51:120–27. doi: 10.1016/j.ijsu.2018.01.008
9. Sah BK, Zhang R, Zhang H, Li J, Yuan F, Ma T, et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. (2020) 11:6093. doi: 10.1038/s41467-020-19965-6
10. Li Z, Shan F, Ying X, Zhang Y, E JY, Wang Y, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA Surg. (2019) 154:1093–101. doi: 10.1001/jamasurg.2019.3473
11. Martin-Romano P, Solans BP, Cano D, Subtil JC, Chopitea A, Abreja L, et al. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS ONE. (2019) 14:e0215970. doi: 10.1371/journal.pone.0215970
12. Wang XG, Liu YH, Qian MX. Comparative efficacy of levopraziquantel and praziquantel in the treatment of schistosoma japonicum infection. Zhonghua Wei Ke Za Zhi. (1987) 26:476–8, 511.
13. Ma F, Zhang Y, Peng L, Zhang Z, Yang W, Chai J, et al. Which is the optimal management for locally advanced gastric cancer patients with TRG 0 and 1 after R0 resection? Ann Transl Med. (2020) 8:948. doi: 10.21037/atm-20-3986
14. Barzi A, Choi A, Tsao-Wei D, Iqbal S, El-Khoueiry A, Agafitei D R, et al. Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFIRI7 in Patients with Stage II and III Rectal Cancer. Oncologist. (2020) 25:e1879–85. doi: 10.1634/theoncologist.2020-0642
15. Sym SJ, Chang HM Ryu MH, Lee JG, Kim TW, Youk JH, et al. Neoadjuvant docetaxel, capcitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol. (2010) 17:1024–32. doi: 10.1245/s10434-009-0838-1
16. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. (2020) 86:102017. doi: 10.1016/j.ctrv.2020.102017
17. Mawalla B, Yuan X, Luo X, Chalya PL. Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Res Notes. (2018) 11:21. doi: 10.1186/s13104-018-3137-8
18. Maene C, Salih R, Van Nieuwenhuysen E, Han SN, Concin N, Vergote I. Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer. Int J Gynecol Cancer. (2021) 31:824–28. doi: 10.1136/ijgc-2021-002432
19. Ou W, Li N, Wang SY Li J, Liu QW, Huang QA, et al. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001). Cancer. (2016) 122:740–7. doi: 10.1002/cncr.29800
20. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. (2016) 67:93–9. doi: 10.3322/caac.21388
21. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. (2011) 14:101–12. doi: 10.1007/s10120-011-0041-5
22. Kim JH, Park SR Ryu MH, Ryoo BY, Kim KP, Kim BS, et al. Phase II Study of Induction Chemotherapy with Docetaxel, Capcitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Res Treat. (2018) 50:518–29. doi: 10.4143/crt.2017.005
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. (2009) 45:228–47. doi: 10.1016/j.ejca.2008.10.026
24. Yang HX, Woo KM, Sima CS, Bains MS, Adusumilli PS, Huang J, et al. Long-term survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy. Ann Surg. (2017) 265:431–37. doi: 10.1097/SLA.0000000000001708
25. Dassen AE, Bernards N, Lemmens VE, van de Wouw YA, Bosscha K, Greeners GJ, et al. Phase II study of docetaxel, cisplatin and capcitabine as preoperative chemotherapy in resectable gastric cancer. World J Gastrointest Surg. (2016) 8:706–12. doi: 10.4240/wjgs.v8.i10.706
26. Sasaki K, Onodera S, Otsuka K, Satomura H, Kurayama E, Kubo T, et al. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Med Oncol. (2017) 34:139. doi: 10.1007/s12032-017-0997-z
27. Ozdemir N, Abali H, Vural M, Yalcin S, Oksuzoglu B, Civelek B, et al. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOFAX study. Cancer Chemother Pharmacol. (2014) 74:1139–47. doi: 10.1007/s00280-014-2586-6
28. Xiong YQ, Sun HC, Zhu XD, Zhang W, Zhuang PY, Zhang JB, et al. Bevacizumab enhances chemosensitivity of hepatectal carcinomas to adriamycin related to inhibition of survivin expression. J Cancer Res Clin Oncol. (2011) 137:505–12. doi: 10.1007/s00432-010-0914-8
29. Kano M, Hayano K, Hayashi H, Hanari N, Gunji H, Toyozumi T, et al. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis. Ann Surg Oncol. (2019) 26:1805–13. doi: 10.1245/s10434-019-07299-7
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yu, Wang, He and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.